Erasca, Inc. (NASDAQ:ERAS) is among the most profitable stocks in each sector so far in 2026. On March 18, JPMorgan lifted the price target on Erasca, Inc. (NASDAQ:ERAS) to $25 from $24 and maintained an Overweight rating. This upward price revision is based on the firm’s model adjustments within the SMID-cap biotechnology group.
Back on March 13, Stifel reaffirmed a Buy rating on Erasca, Inc. (NASDAQ:ERAS) with a price target of $20. This comes after the company’s Q4 results, in which it reported a net loss of $29.1 million for the quarter and $124.6 million for 2025.
adriaticfoto/Shutterstock.com
Additionally, Erasca, Inc. (NASDAQ:ERAS) maintained cash and cash equivalents of $341.8 million as of the year-end. What bolsters the case for the company is its nearly $434 million in pro forma cash to fund operations in the latter half of 2028. Stifel highlights that the cash runway stretches past key ERAS-0015 clinical catalysts planned for the first half of this year and the next.
On the same day, H.C. Wainwright elevated the price target on Erasca, Inc. (NASDAQ:ERAS) from $15 to $20. This optimism is driven by the trial data, which demonstrated two confirmed partial responses and one unconfirmed partial response in patients living with tumors. The firm has an unchanged Buy rating on the stock.
Erasca, Inc. (NASDAQ:ERAS) is a California-based clinical-stage precision oncology company that provides solutions for patients with RAS/MAPK pathway-driven cancers. The company’s core therapies include ERAS-0015, ERAS-4001, and ERAS-12.
While we acknowledge the potential of ERAS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.